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Abstract
Background: Local ablative techniques are emerging in patients with oligometastatic disease from colorectal
carcinoma, commonly described as less invasive than surgical methods. This single arm cohort seeks to determine
whether such methods are suitable in patients with comorbidities or higher age.
Methods: Two hundred sixty-six patients received radiofrequency ablation (RFA), CT-guided high-dose rate
brachytherapy (HDR-BT) or Y90-radioembolization (Y90-RE) during treatment of metastatic colorectal cancer (mCRC).
This cohort comprised of patients with heterogenous disease stages from single liver lesions to multiple organ
systems involvement commonly following multiple chemotherapy lines. Data was reviewed retrospectively for
patient demographics, previous therapies, initial or disease stages at first intervention, comorbidities and mortality.
Comorbidity was measured using the Charlson Comorbidity Index (CCI) and age-adjusted Charlson Index (CACI)
excluding mCRC as the index disease. Kaplan-Meier survival analysis and Cox regression were used for statistical
analysis.
Results: Overall median survival of 266 patients was 14 months. Age ≥ 70 years did not influence survival after local
therapies. Similarly, CCI or CACI did not affect the patients prognoses in multivariate analyses. Moderate or severe
renal insufficiency (n = 12; p = 0.005) was the only single comorbidity identified to negatively affect the outcome
after local therapy.
Conclusion: Interventional procedures for mCRC may be performed safely even in elderly and comorbid patients.
In severe renal insufficiency, the use of invasive techniques should be limited to selected cases.
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Background
Age is a major risk factor for colorectal cancer (CRC)
and cancer in general [1]. Elderly patients often suffer
from comorbidity and reduced organ function thus
requiring particular considerations when making treat-
ment decisions. Additionally elderly patients present a
very heterogeneous group with chronological age being
insufficient to describe individual resources and deficits.
Contributing to these difficulties in decision making,
elderly patients are underrepresented in cancer trials
while they account for most of the actual patients [2]:
When analyzing 495 NCI (National Cancer Institute)
studies, Lewis et al. found that only 32% of cancer trial
participants were age 65 years and older, in contrast to
61% in the US cancer population [3]. Other authors
have published similar results, with an even greater
difference for patients aged 70 years and older [4].
Although there is evidence that age should not be a
reason to refrain from surgery and chemotherapy, most
studies comprise a higher age and comorbidities as
exclusion criteria [5–7]. In clinical practice, patients at
higher age or with comorbidities often receive the
recommended chemotherapies at reduced doses outside
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the standard prescription [8–10]. Yet, the effectiveness
of such adapted therapy regimen is unknown.
Local ablative treatments (LAT, e.g. radiofrequency/
microwave ablation and interstitial HDR-brachytherapy)
as well as locoregional therapies (e.g. Y90 radioemboliza-
tion) offer local tumor control and extensive cytoreduc-
tion with low morbidity and mortality. In oligometastatic
disease with few tumor sites and limited number of me-
tastases, LAT can achieve long-term disease control by
complete tumor ablation in patients not eligible for sur-
gery [11]. In contrast, locoregional therapies such as Y90
radioembolization may contribute to the overall survival
of selected patient by improving the local response in
liver-dominant disease or by providing a salvage treatment
in chemo-refractory liver metastases [12, 13]. Accordingly,
the toolbox of local ablative treatments and locoregional
therapies was included in the latest ESMO guideline for
colorectal cancer with oligometastatic disease or liver
dominant, chemo-refractory metastases [14]. In the con-
text of elderly and comorbid patients, data on the efficacy
of LAT is still rare.
This study aims to assess the influence or absence of
negative effects of higher age or comorbiditieson the
outcome after local therapies. We hypothesize that
minimal-invasive local or locoregional techniques add
further value by offering broader treatment options in




We searched our institutional data base for all patients
with mCRC receiving at least one radiofrequency abla-
tion (RFA), high-dose-rate brachytherapy (HDR-BT) or
Y90-radioembolization (Y90-RE) between 2006 and
2010. We included all patients with complete records on
patient history and at least one follow up visit.
The study comprised a total of 266 patients (179
male, 87 female; mean age 66 years). One hundred
ninety-six patients (73.7%) had synchronous metastases
within 12 months after diagnosis of the primary tumor.
Nearly all patients presented with hepatic metastases
(n = 251, 94.4%). Further sites of dissemination included
lung (n = 77, 28.4%), lymphatic (n = 44, 16.5%), osseous
(n = 10, 3.8%) or other metastases (n = 22, 8.3%). Most
of the patients failed at least one (n = 79, 29.7%) or two
(n = 160, 60.2%) lines of chemotherapy compromising ei-
ther irinotecan or oxaliplatin combined with 5-fluorouracil.
Additionally, 169 patients (63.5%) received EGFR or VEGF
inhibiting therapy. Prior surgical treatments included sur-
gery for the primary tumor in 263 patients (98.9%), resec-
tion of hepatic metastases in 91 patients (34.2%) and
resection of lung/other metastases in 34 patients (12.8%).
Throughout the observation period, nearly half of the
patients developed further liver metastases (n = 118,
44.4%) followed by lung metastases (n = 108, 40.6%),
lymphatic metastases (n = 51, 19.2%), osseous metastases
(n = 18, 6.8%) and other (n = 73, 27.4%).
Patients were considered for local ablative treatment
and Y90 radioembolization by a multidisciplinary team
(MDT; including medical, surgical and radiation on-
cologists) depending on their stage of disease (e.g. size
of tumor, number of lesions, tumor sites) as well as
organ function and performance status. Local ablation
was selected in potentially resectable metastases only
if patients had an unfavorable performance status and/
or severe comorbidities (resulting in a high risk of
perioperative morbidity and mortality) or if patients re-
fused surgery. Patients with single lesions up to 3 cm in
diameter were preferably treated by radiofrequency abla-
tion. If the localization and number of metastases or
tumor size above 3 cm limited RFA, interstitial HDR
brachytherapy was applied for oligometastatic disease. Pa-
tients with diffuse, liver-dominant involvement underwent
Y90 radioembolization. In case of tumor progress during
follow-up, patients were reassessed by the MDT for the
next treatment step, i.e. further local treatment strategies
and/or systemic therapy. In total, 732 interventions were
performed.
Local and locoregional therapies
The following image guided techniques were considered
by the MDT (if not eligible for systemic therapy only).
Radiofrequency ablation
Radiofrequency ablation induces a coagulation necrosis of
tumor tissue by generating heat [15]. RFA is considered to
be a safe and effective method with major complications
occurring in 1–5% of patients. Beside limitations
according to proximity to vulnerable organs, RFA under-
lies a heat-sink effect restricting the maximum size of the
coagulation necrosis [16].
In our study, local ablation for smaller lung or liver
metastases (< 3 cm) was performed using CT-guided ra-
diofrequency ablation (LeVeen®, Boston Scientific, Natrick,
United States or Starburst Semi-Flex®, AngioDynamics,
Mountain View, Canada) according to manufacturer’s
specifications. A total of 21 liver and 77 lung RFA inter-
ventions were conducted.
CT guided high-dose rate brachytherapy
CT-guided HDR-BT is an ablative technique utilizing
radiation from an Iridium-192 source in afterloading tech-
nique. Interstitial catheters were inserted by CT-guidance
and subsequent 3D treatment planning was applied
(Oncentra®, Nucletron, Veenendaal, The Netherlands). As
the catheters are fixed within the tumor, the delivery of
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irradiation is not affected by breathing motion. As a con-
sequence, dose delivery to the tumor is highly accurate
and exposure of healthy tissues or risk organs can be re-
duced to a minimum [17].
Since HDR-BT has no systematic restrictions for tumor
size and location close to vessels, it was preferably indi-
cated if multiple tumors were present as well as in larger
(> 3 cm) liver or lung metastases or any lymphatic metas-
tases [18–20]. To ensure a complete ablation, a target
dose of 20Gy in a single session was subscribed [21].
HDR-BT was mainly used for liver ablations (n = 422), as
well as for ablation of lung metastases (n = 52), lymphatic
nodes (n = 9) and other tumor sites (n = 8).
Y90-radioembolization
If number, size or location of liver metastases exceeded
the capabilities of local ablation by RFA or HDR-BT,
patients were subsequently evaluated for loco-regional
radioembolization using microspheres labeled with the
beta-emitter Yttrium-90 (half-life 64 h; mean energy
0.96 MeV) administered through an angiographic catheter
to the liver arteries [22, 23]. Multinodular liver me-
tastases were treated in 96 cases by 142 radioemboli-
zations using Y90 resin microspheres (SIR-Spheres®,
Sirtex Medical, Lane Cove, Australia), the required
dose was calculated previously according to the body-
surface area method after an initial evaluation with
Technecium-99 m macro-aggregated albumin (LyoMAA,
Covidien, Neustadt, Germany).
Comorbidity measurement
To assess comorbidities, we used the Charlson Comor-
bidity Index (CCI) which is validated in older patients
with the option to calculate an age adjusted index
(Charlson Age Comorbidity Index, CACI) [24, 25] to
predict mortality in a range of comorbid conditions. 19
comorbidity items were included and each condition
was assigned a score of 1, 2, 3 or 6 (see Table 3), de-
pending on the risk of death associated with each one.
The sum of these items (between 0 and 30) formed the
final comorbidity index (CCI, CACI) that has been
established as a predictor of patient outcome and mor-
tality in different settings and larger populations includ-
ing cancer patients [26]. The index disease, metastatic
colorectal cancer, was excluded when calculating the
index. Additional information was assessed regarding
typical cardiovascular risk factors not included within
the CCI (e.g. hypertension, hyperlipidemia, obesity).
All information on comorbidity was recorded at baseline.
Statistical analysis
SPSS 21.0 (IBM®, New York, USA) was used for the
complete analysis set. Comorbidity items including the
summary within the CCI/CACI, patient age and key
characteristics of disease and treatment underwent a
stepwise Cox regression analysis. All baseline variables
were initially analyzed in a univariate Cox regression. Any
variable scoring a p-value < 0.1 was then included in a
multivariate Cox proportional hazard model. Tables 3 and
4 give a summary of the main analysis with p-values,
harzard ratios (HR) and 95% confidence intervals (95%
CI). Statistical significance in the multivariate analysis was




A total of 732 procedures were performed in all patients,
an overview is given in Table 1. All survival data were
Table 1 Overview on procedures and outcome
Median overall survival (months)a
Patients Procedures Patient age Comorbidity
n n ≥ 70 years < 70 years CCI ≥ 3 CCI < 3
RFA 60 99 26.7 m 24.3 m 24.0 m 26.2 m
liver 18 21 (p = 0.76) (p = 0.16)
lung 42 77
other 1 1
HDR-BT 192 491 19.1 m 18.2 m 16.4 m 18.9 m
liver 176 422 (p = 0.83) (p = 0.43)
lung 29 52
lymph node 9 9
other 8 8
Y90-RE 96 142 6.9 m 6.5 m 5.3 m 6.9 m
(p = 0.86) (p = 0.21)
astatistics for overall survival according to Cox regression analysis; p-values (bold) refer to the comparison of survival between age/comorbidity groups
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measured beginning with the first treatment at our
institution.
RFA patients
Patients initially presenting with singular, small metas-
tases (< 3 cm) confined to lung (n = 42) or liver (n = 18)
were treated by radiofrequency ablation yielding a me-
dian survival of 26.7 months and 24.4 months (includ-
ing further local ablative treatments and/or systemic
therapies in case of disease progression). A single RFA
treatment was used for the ablation of a vertebral me-
tastasis. 50 out of 60 patients (83%) treated by RFA
underwent multiple RFA sessions and/or further treat-
ment by HDR-BT for recurrent metastases.
CT-guided HDR brachytherapy patients
Oligonodular and larger metastases were treated by
HDR-BT. Patients with liver metastases eligible for
HDR-BT at their first presentation in our department
achieved a median survival of 18.1 months (n = 176).
Initially applying HDR-BT to lung metastases, a median
survival of 29.6 months was observed (n = 29). Lymphatic
nodes and other infrequent localizations of metastases
(e.g. adrenal glands, pancreas) were treated exclusively by
HDR-BT with a corresponding median survival of 17.0 to
26.7 months. In patients with multiple tumor sites or dis-
ease progression during follow up, HDR-BT was repeated
(n = 143) or Y90-RE performed (n = 28).
Radioembolization patients
Ninety- six patients with diffuse liver metastases under-
went Y90-RE with a median survival of 6.7 months. 68
of these patients who had failed first and second line
chemotherapy including variable treatment cycles with
oxaliplatin, irinotecan and 5-fluorouracil demonstrated
a significantly shorter median survival of 5.8 months
in univariate and multivariate Cox regression analyses
(p < 0.001). However, 19 salvage patients (28%) undergo-
ing Y90 radioembolization had a survival of at least
9 months with long-term survivors reaching a survival of
nearly 30 months. All salvage patients treated by Y90-RE
in this cohort represent a majority of patients in a dedi-
cated prognostic analysis which can be reviewed for sup-
plementary information [27].
Impact of palliative chemotherapy after first
interventional treatment
A total of 120 patients (45%) received further chemo-
therapy after the first local treatment. These patients
demonstrated an improved survival of 22.0 vs. 16.1 months
compared to patients without further systemic therap-
ies (p = 0.009; HR 0.71; 95% CI 0.55–0.92).
Outcome by patient characteristics
Overall patient characteristics are outlined in Table 2.
Survival in all patients accounted for 14 months, survival
analysis was conducted using a stepwise Cox regression
analysis. Nearly all patients suffered from liver metasta-
ses (n = 251). Patients with an initial positive N stage (n
Table 2 Patient characteristics
n %




Mean age (SD) in years 63.0 (+/− 9.7)
Primary tumor
located in Colon (C18) 151 56.77
Rectosigmoid junction (C19) 18 6.77
Rectum (C20) 98 36.84
T1,T2 29 10.90
T3,T4 227 85.30
T missing 10 3.80
N0 74 27.80
N1,2 179 67.30
N status missing 13 4.90
Synchronous metastases 166 62.41
Prior treatment
Systemic chemotherapy 248 93.23
Median lines of chemotherapy (range) 2 (0–8)
Radiochemotherapy 30 11.28
Surgery for colorectal primary 263 98.87
Radiation therapy for colorectal primary 21 7.89
Surgery for liver metastases 91 34.21
Other local treatment for liver metastases 40 15.04
Surgery for lung metastases 14 5.26
Surgery for other metastases 20 7.52
Local therapy for other metastases 5 1.88
First interventional treatment
Mean age (SD) in years 66,5 (+/−9.6)
Age > 70 years 89 33.5
Median Karnofsky index (range) in % 80 (50–100)
Liver metastases 251 96.99
Liver metastases only 121 45.50
Liver involvement > 25% 45 16.92
Lung involvement 100 37.60
Other 83 31.20
≥ 2 organ systems involved 140 52.63
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= 179) and metachronous lymph node metastases (n =
44) had a poorer prognosis (13.1 vs 17.0 months; 9.8 vs
16.1 months) after first interventional treatment in uni-
variate analysis, yet multivariate regression analysis did
not demonstrate a significant influence on overall sur-
vival (p = 0.25 and p = 0.17; respectively).
Synchronous metastases at first diagnosis (n = 166) only
had significant influence in univariate analysis (p = 0.036)
but not in multivariate analysis (p = 0.90). Metachro-
nous pulmonary metastases had no impact on survival
(p = 0.55).
Systemic therapy options after initiation of interven-
tional therapy were stratified by previous failure of either
oxaliplatin or irinotecan based combined regimen (second
line, n = 79) or failure of both (third line, n = 160). Patients
without prior chemotherapy were classified to first line
(n = 27), including patients with contraindications to
systemic therapy. A median survival of 13.2 vs. 16.6 months
was observed in patients receiving third line therapy com-
pared to patients in earlier lines of therapy without prog-
nostic influence in multivariate analysis (p = 0.30).
If third line patients were still eligible for local-ablative
techniques (RFA and/or HDR-BT), the median survival
reached 17.5 months (n = 114).
The complete multivariate analysis is demonstrated in
Table 4.
Age analysis
Our cohort included 89 patients (33.5%) 70 years or older.
This patient group demonstrated no altered survival as
compared to younger patients after first interventional
therapy in a Cox regression analysis (p = 0.19; HR 0.84;
95% CI 0.64–1.10). Median survival in the subgroup of
elder patients was 16.6 vs. 13.2 months as shown in Fig. 1.
In patients older than 70 years initial or additional lymph-
atic metastases were of no prognostic value (p = 0.11; HR
1.24; 95% CI 0.95–1.61 and p = 0.23; HR 1.62; 95% CI
0.74–3.54), just as for heavily pretreated patients with at
least three lines of systemic chemotherapy (p = 0.18;
HR 1.23; 95% CI 0.91–1.67). Survival of elderly versus
younger patients was similar regarding the first tech-
nique applied (RFA, HDR-BT or Y90-RE) in regression
analysis, see Table 1.
Comorbidity analysis (CCI, CACI)
With a sum of 3 points or more for the CCI, 43 patients
(16.2%) displayed severe comorbidities at baseline. These
comorbidities were significantly more frequent in older
patients ≥70 years (n = 21; 23.6%) than in younger patients
< 70 years (n = 22; 12.4%; p = 0.023; Chi-Square test). Ac-
cording to the age adjusted CACI, a total of 112 patients
(42.1%) were considered with severe comorbidities at first
therapy. An overview of CCI/CACI in the patient cohort
is given in Table 3.
In a univariate Cox regression, both CCI or CACI ran-
ging from 0 to 7 and 0–8 had no significant impact on the
patients prognosis (p = 0.82; p = 0.86), respectively. Com-
parison of patients with severe comorbidities (CCI ≥ 3)
versus no or moderate comorbidities demonstrated no
significant influence on overall survival either (18.8 months
vs. 21.9 months; p = 0.41; see Fig. 2). Regression analysis
of all single items summarized in the index (see Table 3)
revealed a significant influence of moderate or severe
renal disease in 12 patients (p = 0.005). Two patients with
gastric or duodenal ulcer died after 3.7 and 5.7 months,
respectively (p = 0.006). Patients with chronic pulmonary
disease (n = 29) had a lower hazard ratio (p = 0.006; HR
0.61; 95 CI 0.38–0.99). No other comorbidity item had a
considerable impact, despite 55 patients suffering from
peripheral vascular disease and 36 patients with a history
of myocardial infarction or coronary heart disease (p =
0.81 and p = 0.38). Multivariate regression analysis finally
confirmed a statistical significant impact of moderate or
severe renal disease in all patients (p = 0.005).
Apart from the conditions reflected in the CCI, 116 pa-
tients had been diagnosed with hypertension (43.6%), 18
patients with obesity (6.8%) and 20 with hyperlipidemia
(7.5%). None of these factors demonstrated a significant
influence on survival as demonstrated in Table 4.
Discussion
Interventional oncology in elderly patients
Metastatic colorectal cancer continues to be a major
therapeutic challenge especially in elderly patients as
prevalence of comorbidity is considered to be more fre-
quent compared to the background population [28].
The corresponding interaction between cancer and
comorbidity, and whether comorbidity leads to cancer
Fig. 1 Overall survival by age. Kaplan Meier estimation for overall
survival after first treatment by age < 70 (13.2 months; n = 177) and
age≥ 70 (16.6 months; n = 89), no statistical difference between
groups (p = 0.19; Cox regression analysis)
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diagnosis in earlier or later stages, is still object to ongoing
discussions [29]. Furthermore, elderly and multimorbid
patients are often not eligible for surgery or efficacious
polychemotherapies [30].
In our group of metastatic CRC patients, about 62%
had comorbidities according to the CCI. Adding condi-
tions as hypertension, hyperlipidemia and obesity, 71%
of patients were suffering from comorbidities, which is
far more frequent than in other studies applying the CCI
reporting a prevalence between 32 and 41% in metastatic
or non-metastatic CRC patients [31].
Median survival after RFA as first local treatment of
liver metastases was 24.4 months in our patients, which
is consistent with existing data ranging from 24 to
36 months [32].
As HDR-BT is usually applied in metastases exceed-
ing the technical feasibility of RFA in size and number,
thus adding an unfavorable prognosis bias, a corre-
sponding median survival of 18.1 months was found in
those patients. A retrospective analysis by Collettini et al.
demonstrated a comparable median survival of 18 months
after HDR-BT of colorectal liver metastases [33].
Most patients undergoing Y90-radioembolization had
previously failed all accessible chemotherapies leading to
a median survival of 5.8 months in this group. However,
one quarter of these patients survived 9 or more months
including a small group of long term survivors > 2 years
indicating that patient selection is of utmost importance
in a salvage population [34]. This could be shown by our
group in a previous study regarding the prognostic value
of Karnofsky index, tumor load and tumor markers in
patients undergoing Y90-radioembolization to help
selecting appropriate patients [27].
When applying CCI and CACI to measure the prognos-
tic impact of comorbidities in our patients, we did not
observe a relation of higher index values with overall
Table 3 Prevalence of comorbidities according to the Charlson Comorbidity index
CCIa condition n % p-value° HR (95% CI)
1 myocardial infarction, coronary artery disease 36 13,5 0.38 0.85 (0.58–1.23)
congestive heart failure 15 5,6 0.62 0.87 (0.51–1.50)
peripheral vascular disease 55 20,7 0.81 0.96 (0.71–1.31)
cerebrovascular disease 13 4,9 0.58 0.85 (0.48–1.52)
dementia 0 0
chronic pulmonary disease 21 7,9 0.046 0.61 (0.38–0.99)
connective tissue disorder 2 0,8 0.93 0.94 (0.23–3.78)
peptic ulcer disease 2 0,8 0.006 7.40 (1.80–30.50)
mild liver disease 10 3,8 0.26 1.44 (0.76–2.72)
diabetes without complications 42 15,8 0.94 0.99 (0.70–1.40)
2 diabetes with end-organ damage 17 6,4 0.74 0.92 (0.55–1.52)
hemiplegia 1 0,4 0.70 1.48 (0.21–10.61)
moderate/severe renal disease 12 4,5 0.005 2.3 (1.29–4.13)
any tumor without metastases (incl. Leukemia, lymphoma) 34 12,8 0.89 1.03 (0.71–1.50)
3 moderate/severe liver disease 3 1,1 0.33 1.77 (0.57–5.55)
6 metastatic solid tumor (mCRC excluded) 0 0
AIDS 0 0
8 AIDS and any tumor 0 0
aage adjusted index CACI adds 1 point for each decade after 40 years
°statistics for overall survival according to univariate Cox regression, variables with univariate p < 0.1 are processed in Table 4
Fig. 2 Overall survival by CCI. Kaplan Meier estimation for overall
survival after first treatment separated by Charlson Comorbidity Index
< 3 (21.9 months; n = 223) and≥ 3 (18.1 months; n = 43); no statistical
difference between groups (p = 0.41; Cox regression analysis)
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survival. It should be noted that about 42% of all patients
had severe comobidities according to the age-adjusted
index (CACI≥3). This finding supports the assumption
that local ablative therapies such as RFA or HDR-BT, or a
locoregional treatment such as Y90 radioembolization,
can be safely applied in risk patients with a moderate tox-
icity profile or adverse event rate, respectively.
A similar relationship was seen recently by Jehn et al. in
patients undergoing systemic therapy for mCRC as CCI
and age showed no influence on survival [35]. In this
population, adverse events were not found to be more fre-
quent in elderly patients, although a significantly higher
CCI was observed. Also response rates and survival were
balanced irrespective of age and comorbidity. Further
studies even discuss inferior outcome in younger patients,
most probably caused by more aggressive tumor biology
as compared to elder patients [36, 37]. With regard to our
patients treated by local therapies, we observed a similar
trend potentially related to a more favorable tumor biol-
ogy in the eldery.
Implications
Our study has demonstrated that older age or a higher
rate of comorbidities with age (CCI and CACI) do not
influence survival in metastatic colorectal cancer when
patients are selected for local or loco-regional ablation
by RFA, HDR-BT or Y90 radioembolization. A poorer
survival was only seen in patients with moderate or se-
vere renal impairment in our multivariate analysis. Renal
disease in general is associated with a poor prognosis
and has been reported to have a specifically negative im-
pact on survival in different cancer populations [38].
Limitations
A possible source of error in our analysis may result from
data being derived from discharge diagnoses or follow up
documentation in our own medical hospital records. Con-
ditions treated by the general practitioner or subsequently
in other hospitals may not have been completely repre-
sented in our data as a result of the studies retrospective
nature. Furthermore, our sample is not necessarily repre-
sentative for all mCRC patients with a comparatively high
frequency of comorbidities in our cohort as compared to
other studies. However, we hypothesize that these finding
exclude a positive selection in our cohort.
Conclusion
The tool box of image guided treatments proved to be safe
and applicable even in patients of higher age or patients
presenting with comorbidities. Our study results support
offering ablative treatments to metastatic colorectal cancer
patients even at advanced age or high Charlson indices.
Abbreviations
CACI: Charlson Age Comorbidity Index; CCI: Charlson Comorbidity Index;
CT: Computed tomography; ESMO: European Society for Medical Oncology;
HDR-BT: High-dose rate brachytherapy; mCRC: metastatic colorectal cancer;
MRI: magnetic resonance imaging; RFA: Radiofrequency ablation; Y90-
RE: Y90-radioembolization
Table 4 Stepwise Cox regression analysis of key characteristics at baseline including CCI items with univariate p < 0.1 (all items of
CCI are shown in Table 3)
Variable Univariate p HR (95% CI) Multivariate p* HR (95% CI)
CCI items p < 0.1
Chronic pulmonary disease 0.046* 0.61 (0.38–0.99) 0.30 0.76 (0.45–1.28)
Peptic ulcer disease 0.006* 7.40 (1.80–30.50) 0.17 2.75 (0.65–11.69)
Moderate/severe renal disease 0.005* 2.3 (1.29–4.13) 0.005 2.46 (1.32–4.57)
Comorbidities not included in CCI
Hypertension 0.54 0.93 (0.72–1.20)
Obesity 0.32 0.77 (0.47–1.28)
Hyperlipidemia 0.48 0.84 (0.51–1.37)
Patient and treatment characteristics
Age > 70 years 0.19 0.84 (0.64–1.10)
CCI≥ 3 0.41 1.15 (0.82–1.62)
Positive N stage of primary 0.004* 1.27 (1.08–1.50) 0.25 1.11 (0.93–1.33)
Synchronous metastases 0.036* 1.36 (1.02–1.81) 0.90 0.98 (0.71–1.35)
Metachronous lymph node metastases 0.032* 1.44 (1.03–2.00) 0.17 1.31 (0.89–1.91)
Metachronous pulmonary metastases 0.55 1.09 (0.83–1.43)
1st/2nd Line vs. 3rd Line treatment 0.001* 0.83 (0.77–0.90) 0.30 0.89 (0.72–1.1)
Salvage treatment in Y90-RE 0.001* 2.17 (1.37–3.45) < 0.001 4.35 (3.06–6.17)
*multivariate Cox regression analysis including all variables p < 0.1 in univariate analysis
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